FDA Approvals of Lecanemab and Donanemab Spark Divided Response Among Healthcare Professionals
Key Insights
The FDA granted approval to both Eisai/Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) for early Alzheimer's disease (search) treatment, marking significant developments in amyloid-targeting therapies.
Healthcare professionals express mixed reactions, with some celebrating the breakthroughs while others raise concerns about modest efficacy, safety risks, and cost-benefit ratios.
The European Medicines Agency's recent rejection of lecanemab highlights ongoing debates about the risk-benefit profile of these new Alzheimer's treatments.
The landscape of Alzheimer's disease (search) treatment has witnessed significant shifts with the FDA's approval of two novel monoclonal antibody therapies, though healthcare professionals remain divided on their clinical impact.
Eli Lilly's donanemab (Kisunla) secured FDA approval based on demonstrating statistically significant reduction in clinical decline using the integrated Alzheimer's Disease (search) Rating Scale (iADRS). Anne White, Eli Lilly's executive vice president, highlighted the drug's "very meaningful results" for early symptomatic Alzheimer's disease patients.
This approval follows both accelerated and traditional FDA approvals of Eisai and Biogen's lecanemab (Leqembi) in early and mid-2023, establishing a new class of amyloid plaque (search)-targeting treatments.
Clinical Community Response
Healthcare professionals have expressed varying levels of enthusiasm about these developments. Neurologist Miles Cobia described being "cautiously optimistic" about lecanemab while acknowledging that "many answers" were still needed. Dr. Mikkael A. Sekeres notably characterized lecanemab as "no panacea," pointing to its relative impact versus placebo.
For donanemab, psychologist Matt Wall celebrated the "incredible news," suggesting progress in treatment development. However, Dr. Christin Glorioso tempered expectations, noting "much to improve in terms of safety and efficacy."
Safety and Efficacy Concerns
Medical professionals have raised specific concerns about both treatments, particularly regarding:
- Risk of amyloid-related imaging abnormalities
- Potential for cerebral hemorrhage
- Modest clinical benefits compared to placebo
- Overall risk-benefit profile
Regulatory Divergence
Adding to the complexity, the European Medicines Agency recently rejected lecanemab's license application, stating that "the benefits of treatment are not large enough to outweigh the risks." This decision highlights the ongoing international debate about the value proposition of these treatments.
Clinical Implementation Challenges
Healthcare providers face practical challenges in prescribing these medications. As physician Jessamy Bagenall noted, clinicians must navigate the "difficulty in prescribing [a] drug with uncertain benefits for patients often desperate for something."
Market Impact and Access
The approval of these treatments has prompted discussions about pricing and accessibility. While some HCPs have noted improved affordability compared to earlier therapies, concerns about cost-effectiveness persist given the modest clinical benefits observed.
Future Outlook
Dr. Richard Simpson's assessment captures the prevailing sentiment: while there is "room for optimism and avenues to explore," those seeking a "magic bullet" may be disappointed. The medical community continues to evaluate these treatments' role in the broader context of Alzheimer's disease (search) management.